support

# Translational Assessment: ACSL4-Driven Ferroptotic Priming in AD-Associated White Matter Degeneration

## Executive Summary

This hypothesis presents a mechanistically compelling yet speculative target for Alzheimer's disease intervention. While ACSL4 is a druggable enzyme with established roles in ferroptosis, significant translational gaps exist between the current preclinical evidence and a viable therapeutic strategy. The hypothesis benefits from strong biological plausibility but lacks direct pharmacological validation in AD-relevant models.

---

## 1. TARGET DRUGGABILITY ASSESSMENT

| Criterion | Assessment | Confidence |
|-----------|------------|------------|
| **Enzyme Class** | ATP-dependent ligase (ACSL family) | High |
| **Active Site Tractability** | Well-defined CoA/ATP binding pockets | Moderate |
| **Selectivity Challenge** | 6 ACSL isoforms (ACSL1,3,4,5,6) with overlapping substrate specificity | High concern |
| **CNS Penetration** | Essential for any AD indication | Critical unknown |
| **Gene Family Complexity** | Functional redundancy may limit efficacy and increase toxicity | Significant concern |

**Key Druggability Issues:**
- ACSL4 shares ~70% catalytic domain homology with other ACSL family members
- Isoform-selective inhibition has proven technically challenging with small molecules
- Knockout studies show compensatory upregulation of ACSL1 in some contexts
- Blood-brain barrier penetration remains entirely unaddressed

**Druggability Score: 0.55** (Moderate - enzyme is tractable but selectivity/CNS delivery are major hurdles)

---

## 2. EXISTING TOOL COMPOUNDS

### Direct ACSL4 Inhibitors
| Compound | Evidence Quality | Limitations |
|----------|------------------|--------------|
| **Rosiglitazone** | In vitro biochemical studies; inhibits ACSL4 at μM concentrations | Non-selective (PPARγ agonist); thiazolidinedione class has known safety liabilities |
| **Thiazolidinedione analogs** | Some SAR studies exist | Not CNS-penetrant; off-target effects |
| **ACG-110** | Reported ACSL4-selective inhibitor | Limited publication; unverified activity in vivo |

### Indirect Ferro